Benzinga | Mar 5, 2021 07:13AM EST

Aquestive Therapeutics To Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event On March 25 t 9:00 a.m. ET

WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it will host a virtual investor and analyst epinephrine drug delivery research and development event on Thursday, March 25, 2021 at 9:00 am ET.



The event will feature a review of the epinephrine drug delivery program, inclusive of the data from the two Phase 1 PK trials and clinical development strategy, and a Q&A discussion. Presentations will be delivered by members of Aquestive's senior management team and by two prominent Key Opinion Leaders in the field of allergy disorders:

* David Fleischer, M.D., Section Head, Pediatric Allergy and Immunology at Children's Hospital Colorado, Professor of Pediatrics at University of Colorado School of Medicine

* John Oppenheimer, M.D., Clinical Professor of Medicine at UMDNJ Rutgers, Pulmonary and Allergy Associates NJ

A webcast of the virtual R&D event and accompanying slides will be available under "Events and Presentations" in the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations. In addition, the R&D event can be accessed by dialing (833) 640-1722 from the U.S. and (602) 585-9829 internationally, followed by the conference ID: 3598556. The event webcast will be archived for 30 days.